Involvement of N-acetyltransferase human in the cytotoxic activity of 5-fluorouracil

Anti-Cancer Drugs

Volumn 20, Issue 8, 2009, Pages 668-675

  Takubo, Kazuko ^a,b   Tsuchiya, Hiroyuki ^a   Kurimasa, Akihiro ^a   Arnesen, Thomas ^c   Ryoke, Kazuo ^b   Shiota, Goshi ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

5 fluorouracil; Apoptosis; N acetyltransferase human; Proteomic analysis; Squamous cell carcinoma

Indexed keywords

ACYLTRANSFERASE; BLEOMYCIN; ELONGATION FACTOR 1ALPHA; ENOLASE; ENOLASE 1; FLUOROURACIL; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; LIPOCORTIN 5; MESSENGER RNA; METHOTREXATE; MITOMYCIN C; NEDAPLATIN; NUCLEAR AUTO ANTIGENIC SPERM PROTEIN; PROFILIN; PROFILIN I; PROTEIN 14 3 3; PROTEIN CUTA; RAN PROTEIN; SMALL INTERFERING RNA; THYMIDYLATE SYNTHASE; TUBULIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; ENZYME MECHANISM; GENE OVEREXPRESSION; HEP 2 CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SQUAMOUS CELL CARCINOMA; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARYLAMINE N-ACETYLTRANSFERASE; CASPASE 9; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; DOWN-REGULATION; FLUOROURACIL; GENE EXPRESSION; HUMANS; ISOENZYMES; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN BIOSYNTHESIS; PROTEINS; RNA, SMALL INTERFERING; THYMIDYLATE SYNTHASE; TRANSFECTION; UP-REGULATION;

EID: 70349339079     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32832d5159     Document Type: Article

References (26)

1. Yoshida M, Huremia R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 2001; 48:S20-S26.
2. Gennaro ED, Bruzzese F, Caraglia M, Abruzzese A, Budillon A. Acetylation of proteins as novel target for antitumor therapy: review article. Amino Acids 2004; 26:435-441.
3. Monneret C. Histone deacetylase inhibitors. Eur J Med Chem 2005; 40:1-13.
4. Bradshaw RA, Brickey WW, Walker KW. N-terminal processing: the methionine aminopeptidase and N alpha-acetyl transferase families. Trends Biochem Sci 1998; 23:263-267.
5. Brown JL. The N-terminal region of soluble proteins from procaryotes and eukaryotes. Biochem Biophys Acta 1970; 221:480-488.
6. Polevoda B, Norbeck J, Takakura H, Blomberg A, Sherman F. Identification and specificities of N-terminal acetyltransferases from Saccharomyces cerevisiae. EMBO J 1999; 18:6155-6168.
7. Mullen JR, Kayne PS, Moerschell RP, Tsunasawa S, Gribskov M, Shepanski MC, et al. Identification and characterization of genes and mutants for N-terminal acetyltransferase from yeast. EMBO J 1989; 8:2067-2075.
8. Sugiura N, Adams SM, Corriveau RA. An evolutionarily conserved N-terminal acetyltransferase complex associated with neuronasal development. J Biol Chem 2003; 278:40113-40120.
9. Fluge Ø, Bruland O, Akslen LA, Varhaug JE, Lillehaug JR. NATH, a novel gene overexpressed in papillary thyroid carcinomas. Oncogene 2002; 21:5056-5068.
10. Arnesen T, Anderson D, Baldersheim C, Lanotte M,Varhaug JE, Lillehaug JR. Identification and characterization of the human ARD1-NATH protein acetyltransferase complex. Biochem J 2005; 386:433-443.
11. Gautschi M, Just S, Mun A, Ross S, Rücknagel P, Dubaquie Y, et al. The yeast N alpha-acetyltransferase NatA is quantitatively anchored to the ribosome and interacts with nascent polypeptides. Mol Cell Biol 2003; 23:7403-7414.
12. Arnesen T, Anderson D, Torsvik J, Halseth HB, Varhaug JE, Lillehaug JR. Cloning and chracterization of hNAT5/hSAN: an evolutionarily conserved component of the NatA protein N-a-acetyltransferase complex. GENE 2006; 371:291-295.
13. Arnesen T, Gromyko D, Horvli O, Fluge Ø, Lillehaug J, Varhaug JE. Expression of N-acetyl transferase human and human arrest defective 1 proteins in thyroid neoplasms. Thyroid 2005; 15:1131-1136.
14. Arnesen T, Gromyko D, Pendino F, Ryningen A, Varhaug JE, Lillehaug JR. Induction of apoptosis in human cells by RNAi-mediated knockdown of hARD1 and NATH, components of the protein N-a-acetyltransferase complex. Oncogene 2006; 25:4350-4360.
15. Heiderberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957; 30:663-666.
16. Spiegelman S, Sawyer R, Nayak R, Ritzi E, Stolfi R, Martin D. Improving the anti-tumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulatuion. Proc Natl Acad Sci U S A 1980; 77:4966-4970.
17. Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 1990; 48:381-395.
18. Aoki Y, Sato T, Watanabe M, Sasaki M, Tsuneki I, Tanaka K. Neoadjuvant chemotherapy using low-dose consecutive intraarterial infusions of cisplatin combined with 5-fluorouracil for locally advanced cervical adenocarcinoma. Gynecol Oncol 2001; 81:496-499.
19. Christiansen H, Hermann RM, Hille A, Weiss E, Nitsche M, Martin A, et al. Concomitant radiochemotherapy in primary inoperable advanced head and neck cancer with 5-fluorouracil and mitomycin-c. Head Neck 2004; 26:845-853.
20. Ducreux M, Bouche O, Pignon JP, Mousseau M, Raoul JL, Cassan P, et al. Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Oncology 2006; 70:222-230.
21. Uka K, Akita H, Takaki S, Miki D, Kawaoka T, Jeong SC, et al. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol 2007; 42:845-853.
22. Inaba M, Mitsuhashi J. Flow cytometric analysis of cell-killing of 5-fluorouracil in human colorectal cancer cells. Oncol Res 1994; 6:303-309.
23. Xiao Z, Xue J, Sowin TJ, Rosenberg SH, Zhang H. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 2005; 24:1403-1411.
24. Van Tris B, Pinedo HM, Giaccone G, Peters GJ. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol 2000; 11:385-391.
25. Evans RM, Laskin JD, Hakala MT. Assessment of growth-limiting events caused by 5-fluorouracil in mouse cells and in human cells. Cancer Res 1980; 40:4113-4122.
26. Wong CS, Wong VW, Chan CM, Ma BB, Hui EP, Wong MC, et al. Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. Oncol Rep 2008; 20:89-98.